Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 28, 2016; 22(24): 5505-5511
Published online Jun 28, 2016. doi: 10.3748/wjg.v22.i24.5505
Published online Jun 28, 2016. doi: 10.3748/wjg.v22.i24.5505
Table 1 Main results from trials on Escherichia coli Nissle on ulcerative colitis
Efficacy of EcN 1917 in maintanance of UC remission |
Results from major randomized controlled clinical trials |
EcN 200 mg/d is equivalent to Mesalazine 1000 mg/d in mantainance of UC remission[27] |
EcN 400 mg/d is equivalent to to Mesalazine 2400 mg/d in maintanance of UC remission following an acute flare[28] |
EcN 200 mg/d is equivalent to Mesalazine 1500 mg/d in mantainance of UC remission[10] |
Results from minor studies |
Rectal admistration of EcN 40 mL/d is effective in moderate distal active UC[30] |
EcN 200 mg/d is equivalent to Mesalazine 1500 mg/d in maintanance of UC remission[6] |
Table 2 Main potential clinical indications for Escherichia coli Nissle in gastroenterology
- Citation: Scaldaferri F, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J Gastroenterol 2016; 22(24): 5505-5511
- URL: https://www.wjgnet.com/1007-9327/full/v22/i24/5505.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i24.5505